2026-05-31T17:04:08Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/171572026-02-03T11:51:31Zcom_10630_2254col_10630_37959

Resistance acquisition after seven cycles of in vitro bleomycin exposure Burgos-Molina, Antonio Manuel Gil-Carmona, Luisa Lumbreras-Vega, Luis Joaquín Ruiz-Gómez, Miguel José Medicina Bleomycin is an antineoplastic drug that causes DNA damage by intra- and inter-strand crosslink and DNA strand breaks. This drug is used to treat several types of cancer. The aim of this work is to study the effect of Bleomycin on S. cerevisiae cells and select bleomycin-resistant cells to study the process of resistance acquisition to establish new protocols in in vitro drugs exposure. 2019-01-16T11:58:35Z 2019-01-16T11:58:35Z 2019-01-16T11:58:35Z 2019-01-16 conference output https://hdl.handle.net/10630/17157 eng 16th ASEICA International Congress 2018 Valencia (España) 06-08/11/2018 http://creativecommons.org/licenses/by-nc-nd/4.0/ open access Attribution-NonCommercial-NoDerivatives 4.0 Internacional